| Basics |
Corvus Pharmaceuticals, Inc. Common Stock
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.
|
| IPO Date: |
March 21, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$657.95M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.19 | 3.67%
|
| Avg Daily Range (30 D): |
$0.23 | 2.81%
|
| Avg Daily Range (90 D): |
$0.20 | 2.98%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.53M |
| Avg Daily Volume (30 D): |
.91M |
| Avg Daily Volume (90 D): |
.74M |
| Trade Size |
| Avg Trade Size (Sh.): |
190 |
| Avg Trade Size (Sh.) (30 D): |
95 |
| Avg Trade Size (Sh.) (90 D): |
102 |
| Institutional Trades |
| Total Inst.Trades: |
149 |
| Avg Inst. Trade: |
$1.53M |
| Avg Inst. Trade (30 D): |
$1.03M |
| Avg Inst. Trade (90 D): |
$1.31M |
| Avg Inst. Trade Volume: |
.26M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.9M |
| Avg Closing Trade (30 D): |
$.8M |
| Avg Closing Trade (90 D): |
$1.05M |
| Avg Closing Volume: |
328.64K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.2
|
$-.12
|
$-.1
|
|
Diluted EPS
|
$-.54
|
$-.12
|
$-.1
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -15.08M
|
$ -10.16M
|
$ -8M
|
|
Operating Income / Loss
|
$ -38.86M
|
$ -10.57M
|
$ -10.26M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -1.81M
|
$ -11.82M
|
$ 9.69M
|
|
PE Ratio
|
|
|
|
|
|
|
